Our Story
Since 2002, Lilly Ventures has
focused its investments in
great companies with
compelling life science
innovations that have the
potential to create a
pipeline of life-changing
medicines. We partner actively
with our portfolio company
management teams and
provide intellectual, as
well as financial, resources
to accelerate the path to
success.
Our Team
Our collaborative partnership
leverages the collective
experience, deep expertise,
and networks of our
investment professionals for
the benefit of our portfolio
companies.
Our News
Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer
July 19, 2018
Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer
view full storyAeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors
July 16, 2018
Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors
view full storyNimbus Therapeutics Names Adrian Ray, Ph.D., as Senior Vice President of Discovery Biology
July 9, 2018
Nimbus Therapeutics Names Adrian Ray, Ph.D., as Senior Vice President of Discovery Biology
view full storyProtagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting
June 18, 2018
Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting
view full storySurface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930
June 12, 2018
Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930
view full storyNimbus Therapeutics Announces $65 Million in New Financing to Accelerate Pipeline Progress and Expand Discovery Efforts
June 5, 2018
Nimbus Therapeutics Announces $65 Million in New Financing to Accelerate Pipeline Progress and Expand Discovery Efforts
view full storyProtagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer
May 24, 2018
Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer
view full storyProtagonist Therapeutics Appoints Bryan Giraudo to Board of Directors
May 16, 2018
Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors
view full storyAileron Therapeutics Announces Changes to Management
May 15, 2018
Aileron Therapeutics Announces Changes to Management
view full storySutro Initiates First Clinical Trial of CD74-Targeting ADC for Lymphoma & Multiple Myeloma Treatment
April 26, 2018
Sutro Initiates First Clinical Trial of CD74-Targeting ADC for Lymphoma & Multiple Myeloma Treatment
view full storyKymera Appoints Industry Veteran Dr. Joanna Horobin to its Board of Directors
April 23, 2018
Kymera Appoints Industry Veteran Dr. Joanna Horobin to its Board of Directors
view full storySurface Oncology Announces $119.5 Million Aggregate Financing
April 18, 2018
Surface Oncology Announces $119.5 Million Aggregate Financing
view full storyAeglea BioTherapuetics: New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients
April 12, 2018
Aeglea BioTherapuetics: New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients
view full storyTim Clackson, Ph.D., Named to FORMA Therapeutics Board of Directors
April 9, 2018
Tim Clackson, Ph.D., Named to FORMA Therapeutics Board of Directors
view full storyFORMA Therapeutics Achieves Key Objective in Collaboration with Celgene Corporation to Advance a Novel Protein Homeostasis Oncology/Immuno-Oncology Program
April 5, 2018
FORMA Therapeutics Achieves Key Objective in Collaboration with Celgene Corporation to Advance a Novel Protein Homeostasis Oncology/Immuno-Oncology Program
view full storyKymera Therapeutics Announces Discovery Collaboration with GSK to Advance New Treatment Modality
April 4, 2018
Kymera Therapeutics Announces Discovery Collaboration with GSK to Advance New Treatment Modality
view full storySymic Bio Announces 12-Month Results from the SHIELD Trial of SB-030 in Peripheral Vascular Disease
April 2, 2018
Symic Bio Announces 12-Month Results from the SHIELD Trial of SB-030 in Peripheral Vascular Disease
view full storyAeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination Trials
April 2, 2018
Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination Trials
view full storySurface Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of SRF231
March 20, 2018
Surface Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of SRF231
view full storyFirst Patient Enrolled in Cavion Multi-Center Phase 2 Clinical Trial in Epilepsy
March 20, 2018
First Patient Enrolled in Cavion Multi-Center Phase 2 Clinical Trial in Epilepsy
view full storyAileron Therapeutics Appoints Jeffrey A. Bailey to its Board of Directors
March 19, 2018
Aileron Therapeutics Appoints Jeffrey A. Bailey to its Board of Directors
view full storyAeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with Pegzilarginase
March 8, 2018
Aeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with Pegzilarginase
view full storyInCube Portfolio Company Rani Therapeutics Funding Robotic Pill
February 9, 2018
InCube Portfolio Company Rani Therapeutics Funding Robotic Pill
view full storySymic Bio Completes the MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Knee Osteoarthritis
February 7, 2018
Symic Bio Completes the MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Knee Osteoarthritis
view full story